All Eyes on the Legalization of Cannabis

Tuesday, November 8, 2016 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, November 8, 2016 /PRNewswire/ --

Today is not only a politically important day for the

United States, but also a very crucial day for marijuana industries, as many states will hold referendums on the decision to legalize recreational and medical marijuana or not. It is estimated that roughly 30 percent of the US population in nine
of the states will partake in the vote for the historical decision., Inc. (OTC: CIIX), Medicine Man Technologies, Inc. (OTC: MDCL), Cannabics Pharmaceuticals Inc. (OTC: CNBX), Cara Therapeutics Inc. (NASDAQ: CARA), Insys Therapeutics Inc. (NASDAQ: INSY).

According to a report by New Frontier and ArcView Market Research, the regulated cannabis market in the United States is projected to reach more than $7 billion this year. With many states voting today, all eyes will be focused on the Legalization of Cannabis.

Last week, Inc. (OTCQB: CIIX), announced that it will launch the world's first Chinese-language subscriber-only information service specifically focused on emerging growth companies in the Cannabis sector. The content of this service will cover the medical and recreational cannabis markets, the latest trends and technologies in the industry, and any investment opportunities in either private or publicly traded cannabis companies. The subscription service is expected to be launched after January 1st, 2017.

Just today Inc. announces that it will launch the world's first Chinese-language talk show specifically focused on investment opportunities in the Cannabis sector. The content of this talk show will follow the latest trends in both the medical and recreational cannabis markets, explore the promising growth of this new emerging industry, and identify select cannabis equities with the greatest potential for capital appreciation. The five-minute talk show is expected to be launched after December 1st, 2016, and it will be available on the company's official Youtube Channel as well as the Phoenix North America Chinese Channel, which is one of the most popular subscriber-only media platforms in the Chinese-speaking communities.

Warren Wang, founder and CEO of, commented: "Many Chinese investors still have a bias against the cultivation and sales of cannabis and we need to make them aware of the huge potential business opportunities within this industry. In addition, if recreational marijuana is legalized in California, an estimated $1 billion in new tax revenue would be directed toward specific drug use prevention programs and treatment, helping at-risk youth, law enforcement, and medical cannabis research…In 2015, 1.8 million Chinese tourists visited United States. We believe that many of these tourists may be curious about the California cannabis legislation and may come to the state to either experience the American recreational marijuana culture or invest in this emerging market. Our plan to launch a first of its kind Chinese-language talk show focused specifically on the cannabis sector will definitely assist the Chinese-speaking investor in overcoming the language barrier and also help cannabis retailers to attract more potential medical users." Inc. saw  a great opportunity to enter the cannabis sector and holds or held a stake with consulting service company that covers all aspects of cannabis cultivation, Medicine Man Technologies, Inc. (OTCQB: MDCL). The company implemented a risk averse growing environment, applying high-tech indoor cannabis cultivation equipment and works in medical and adult use dispensaries. Medicine Man Technologies assisted Illinois and Nevada licensees to organize these practices after acquiring cultivation and dispensary operational licenses. Currently, the company has reinforced competitive application filings in Maryland and Hawaii and has pre-licensure clients in Texas, California, Florida, Ohio, Arkansas, and Oklahoma and has engaged potential clients in Alaska, Delaware, Utah, Michigan, Nebraska, Puerto Rico, and abroad.

Cannabics Pharmaceuticals Inc. (OTC: CNBX) announced results from the company's latest cancer HTS research overtly conclude that, depending upon the THC/CBD ratio, specific Cannabis extracts are directly contributive to reducing U87MG glioblastoma cell viability. "The Cannabics' method of diagnosis clearly differentiates between a multitude of varied plant extracts and their apoptotic and necrotic effects by utilizing state of the art of High Through-put Screening on cells derived from patients' biopsies; the results of which are visualized in "scans" of the before, during and after effect upon the cancer cells themselves" said Chief Scientist of Cannabics Pharmaceuticals, Dr. Eyal Ballan.

Biotechnology Company, Cara Therapeutics Inc. (NASDAQ: CARA), is pleased to be actively enrolling late stage studies with both IV and oral formulations of CR845 for three significant unmet medical indications. In September 2016, Cara initiated the enrollment of a Phase 2b trial of Oral CR845 in roughly 330 patients for the treatment of pain associated with osteoarthritis and presented positive data at PAINWeek from the Phase 2a study of Oral CR845 in OA. In October, company initiated Phase 1 study with Oral CR845 in hemodialysis patients.

Chairman, President and Chief Executive Officer of Insys Therapeutics Inc. (NASDAQ: INSY), Dr. John N. Kapoor has commented on the company's recent third quarter 2016 noting that Subsys volumes declined in the quarter, and is pleased to have maintained a mid-40 percent market share and believe the product will continue to provide a solid financial foundation for growth and to support the company's R&D efforts. The company is anticipating Drug Enforcement Administration scheduling of Syndros, it's recently FDA approved product for the treatment of cancer induced nausea and vomiting and anorexia related with weight loss in AIDS patients. INSY is excited about their main pipeline and believe that both its spray and cannabinoid platform products will provide opportunities for future growth.

Subscribe Now! Watch us report from NYSE

For "The Latest Buzz in Financial News", SIGN UP & Visit:

Follow us on Twitter for real time Financial News Updates:

Follow and talk to us on Instagram:

Facebook Like Us to receive live feeds:

About, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and pr marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site for advertising such companies. has not been compensated for financial news dissemination and pr services by any company mentioned in our sophiscated article. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on this site along with other financial news pr media services. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit:

For further information:

Media Contact: , +1-877-601-1879


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store